SCHEMBL22979540

SCHEMBL22979540

NNC(=O)c1ccc(Br)cc1OC(F)F

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
OGG1 O15527 1/20 0.42
ALDH1A1 P00352 5/20 0.42
GAA P10253 3/20 0.42
KDM4E B2RXH2 2/20 0.42
CTSD P07339 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
PKM P14618 1/20 0.39
GFER P55789 2/20 0.39
DGAT1 O75907 1/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 1/20 0.38
MAPT P10636 3/20 0.38
LMNA P02545 1/20 0.38
P4HB P07237 1/20 0.38
ALOX15 P16050 1/20 0.37
ADAM17 P78536 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22979955 0.82 MAPT (0.57) ALDH1A1GAAKDM4ECTSDSMN1; SMN2
SCHEMBL5236256 0.81 KDM4E (0.44) ALDH1A1KDM4EKMT2AMEN1PKM
SCHEMBL5236111 0.80 KMT2A (0.46) ALDH1A1GAAKDM4ESMN1; SMN2KMT2A
SCHEMBL15106217 0.80 GSK3B (0.41) ALDH1A1KMT2AMEN1PKMDGAT1
SCHEMBL4338973 0.80 CTSD (0.60) OGG1ALDH1A1GAAKDM4ECTSD
SCHEMBL15105948 0.80 PTGDR2 (0.45) ALDH1A1SMN1; SMN2KMT2AMEN1PKM
SCHEMBL29333898 0.80 DGAT1 (0.42) ALDH1A1KDM4EKMT2AMEN1PKM
SCHEMBL22979567 0.79 MAOA (0.44) OGG1ALDH1A1GAAKDM4ECTSD
SCHEMBL28176626 0.79 ALDH1A1 (0.41) ALDH1A1KMT2AMEN1PKMLMNA
SCHEMBL22987538 0.78 CTSD (0.62) ALDH1A1GAAKDM4ECTSDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114466850-B [1,2,4] Triazolo [1,5-C ] quinazolin-5-amine 拜耳股份有限公司 2024-09-10 CN disclosed
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
EP-4013508-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES Bayer Aktiengesellschaft (DE) 2022-06-22 EP disclosed
CN-114466850-A [1,2,4] triazolo [1,5-C ] quinazolin-5-amines 拜耳股份有限公司 2022-05-10 CN disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES AHR, HRH4, HRH1 OGG1 3575/4885ALDH1A1 597/4885GAA 3740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.